Biogen
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update
Rapport Therapeutics announces financial results for Q3 2024, appoints new Board members, and provides updates on RAP-219 trials in focal epilepsy, peripheral neuropathic pain, and bipolar disorder. The company ended the quarter with $320.7 million in cash, expected to fund operations through 2026.
Cassava's Alzheimer's drug nears P3 readout, but SEC scandal casts long shadow
Cassava Sciences is advancing simufilam through a phase 3 trial, despite SEC controversy over past data integrity. The company aims to release trial results soon, with new leadership emphasizing transparency and ethical practices. The success of simufilam, Cassava's only asset, hinges on these results, which will face heightened scrutiny due to previous data issues.
Ionis reports third quarter 2024 financial results – Company Announcement
Ionis Pharmaceuticals reports Q3 2024 financial results, highlighting progress with WAINUA U.S. launch, olezarsen FDA action date in December 2024, and donidalorsen HAE PDUFA date in August 2025. The company is on track to achieve 2024 financial guidance and increased cash guidance to $2.2 billion. Key pipeline milestones include positive CHMP opinion for WAINUA in the UK, QALSODY approval in China, and ongoing pivotal development programs for olezarsen and donidalorsen.
Ionis reports third quarter 2024 financial results
Ionis Pharmaceuticals reports Q3 2024 financial results, highlighting successful U.S. launch of WAINUA, upcoming FDA action dates for olezarsen and donidalorsen, and reaffirmed 2024 P&L financial guidance with increased cash guidance to $2.2 billion.
ASHG Welcomes 2024–2026 Human Genetics Scholars
ASHG welcomed 2024–2026 Human Genetics Scholars, including Amber M. Abram, Kynon J. Benjamin, Razaq Durodoye, Tania Fabo, Gabrielle Ferra, JP Flores, Renée Fonseca, and Esteban Vazquez-Hidalgo, recognized for research and commitment to diversity, equity, and inclusion in human genetics and genomics.
© Copyright 2024. All Rights Reserved by MedPath